RayKnowChina Research Map
Shortlist0

RecruitingOesophageal squamous cell carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of USTC; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07188103, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. a. Patients with histologically confirmed esophageal squamous cell carcinoma (ESCC) , aged 18-80 years;

    Inclusion criterion 1

  3. b. Unresectable locally advanced, postoperative recurrent, or metastatic ESCC that has progressed on or is intolerant to first-line systemic therapy. For patients who received definitive concurrent chemoradiotherapy (CCRT) , disease progression during or within 6 months post-treatment is considered first-line treatment failure;

    Inclusion criterion 2

  4. e. Eastern Cooperative Oncology Group (ECOG) performance status: 0-2;

    Inclusion criterion 15

  5. Hemoglobin (Hb) ≥ 90 g/L

    Inclusion criterion 6

    White blood cell (WBC) count ≥ 1.5 × 10⁹/L

    Inclusion criterion 7

    Platelet count ≥ 60 × 10⁹/L

    Inclusion criterion 8

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN)

    Inclusion criterion 11

    Total bilirubin ≤ 1.5 × ULN

    Inclusion criterion 12

    Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 60 mL/min

    Inclusion criterion 13

  6. c. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) . All positive regional lymph nodes are counted as a single lesion, while non-regional metastatic lymph nodes are counted per station;

    Inclusion criterion 3

  7. h. Pregnant or lactating women;

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07188103, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • a. Patients with histologically confirmed esophageal squamous cell carcinoma (ESCC) , aged 18-80 years;
  • b. Unresectable locally advanced, postoperative recurrent, or metastatic ESCC that has progressed on or is intolerant to first-line systemic therapy. For patients who received definitive concurrent chemoradiotherapy (CCRT) , disease progression during or within 6 months post-treatment is considered first-line treatment failure;
  • c. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) . All positive regional lymph nodes are counted as a single lesion, while non-regional metastatic lymph nodes are counted per station;
  • d. Adequate major organ function, defined as:
  • Hematology:
  • Hemoglobin (Hb) ≥ 90 g/L
  • White blood cell (WBC) count ≥ 1.5 × 10⁹/L
  • Platelet count ≥ 60 × 10⁹/L
  • Serum biochemistry:
  • Albumin ≥ 25 g/L
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 × ULN
  • Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 60 mL/min
  • Echocardiography:

Left ventricular ejection fraction (LVEF) ≥ 50% (lower limit of normal)

  • e. Eastern Cooperative Oncology Group (ECOG) performance status: 0-2;
  • f. Expected survival ≥ 3 months;
  • g. Voluntarily enrolled, with signed informed consent, and willing to comply with study protocols and follow-up.

Exclusion Criteria:

  • a. Patients with severe organ dysfunction, uncontrolled acute infection, or significant comorbidities;
  • b. Patients with vertebral metastases accompanied by spinal cord compression symptoms;
  • c. Patients with esophagotracheal or esophagomediastinal fistulas;
  • d. Patients with uncontrolled pleural, pericardial, or pelvic effusions requiring repeated drainage;
  • e. Patients with esophageal primary/metastatic lesions invading the heart or great vessels, as assessed by the responsible physician, with a risk of life-threatening hemorrhage;
  • f. Patients with esophageal primary/metastatic lesions invading the trachea or bronchi, as assessed by the responsible physician, with a risk of esophagotracheal fistula;
  • g. Patients not suitable for short-course hypofractionated radiotherapy, as evaluated by the responsible physician;
  • h. Pregnant or lactating women;
  • i. Patients with mental disorders, or those with a history of psychotropic drug abuse and unable to quit;
  • j. Patients who have participated in other drug clinical trials within the past 4 weeks;
  • k. Patients or their families who refuse to participate in the study.

Quoted from ClinicalTrials.gov, NCT07188103, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07188103, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07188103